Funato Michinori, Tsunematsu Yukiko, Yamazaki Fumito, Tamura Chieko, Kumamoto Tadashi, Takagi Masatoshi, Kato Shunsuke, Sugimura Haruhiko, Tamura Kazuo
Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.
Department of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan.
Cancer Sci. 2021 May 1;112(7):2821-34. doi: 10.1111/cas.14919.
Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome, and the majority of patients with LFS have been identified with germline variants in the p53 tumor suppressor (TP53) gene. In the past three decades, considerable case reports of TP53 germline variants have been published in Japan. To the best of our knowledge, there have been no large-scale studies of Japanese patients with LFS. In this study, we aimed to identify Japanese patients with TP53 germline variants and to reveal the characteristics of LFS in Japan. We collected reported cases by reviewing the medical literature and cases diagnosed at the institutions of the authors. We identified 68 individuals from 48 families with TP53 germline pathogenic or likely pathogenic variants. Of the 48 families, 35 (72.9%) had missense variants, most of which were located within the DNA-binding loop. A total of 128 tumors were identified in the 68 affected individuals. The 128 tumor sites were as follows: breast, 25; bones, 16; brain, 12; hematological, 11; soft tissues, 10; stomach, 10; lung, 10; colorectum, 10; adrenal gland, 9; liver, 4; and others, 11. Unique phenotype patterns of LFS were shown in Japan in comparison to those in a large national LFS cohort study in France. Above all, a higher frequency of patients with stomach cancer was observed in Japanese TP53 germline variant carriers. These results may provide useful information for the clinical management of LFS in Japan.
李-弗劳梅尼综合征(LFS)是一种遗传性癌症易感性综合征,大多数LFS患者已被鉴定出p53肿瘤抑制基因(TP53)的种系变异。在过去三十年中,日本发表了大量关于TP53种系变异的病例报告。据我们所知,尚未对日本LFS患者进行大规模研究。在本研究中,我们旨在识别携带TP53种系变异的日本患者,并揭示日本LFS的特征。我们通过查阅医学文献和作者所在机构诊断的病例来收集报告病例。我们从48个家庭中识别出68名携带TP53种系致病或可能致病变异的个体。在这48个家庭中,35个(72.9%)有错义变异,其中大多数位于DNA结合环内。在68名受影响个体中共鉴定出128个肿瘤。128个肿瘤部位如下:乳腺,25个;骨骼,16个;脑,12个;血液系统,11个;软组织,10个;胃,10个;肺,10个;结肠直肠,10个;肾上腺,9个;肝脏,4个;其他,11个。与法国一项大型全国性LFS队列研究相比,日本显示出LFS独特的表型模式。最重要的是,在日本携带TP53种系变异的患者中观察到胃癌患者的频率更高。这些结果可能为日本LFS的临床管理提供有用信息。